Roche Announces Positive Results In Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)

Roche announced positive results from a Phase I trial of R1507, a human monoclonal antibody to target IGF-1R (insulin-like growth factor receptor), in patients with solid tumors. IGF-1 is one of the most potent natural activators of the AKT and MAPK signaling pathways, which promote cell growth and cell survival. The IGF-1R pathway has also been shown to have an important role in mediating the resistance to cytotoxic drugs and EGFR/HER2-targeted agents. [click link for full article]

More: continued here

Filed under: Bones on October 25th, 2007